

# Global Fast-acting Human Insulin Market Growth 2023-2029

https://marketpublishers.com/r/G3DA527E3398EN.html

Date: November 2023 Pages: 111 Price: US\$ 3,660.00 (Single User License) ID: G3DA527E3398EN

# **Abstracts**

The report requires updating with new data and is sent in 48 hours after order is placed.

According to our LPI (LP Information) latest study, the global Fast-acting Human Insulin market size was valued at US\$ million in 2022. With growing demand in downstream market, the Fast-acting Human Insulin is forecast to a readjusted size of US\$ million by 2029 with a CAGR of % during review period.

The research report highlights the growth potential of the global Fast-acting Human Insulin market. Fast-acting Human Insulin are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Fast-acting Human Insulin. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Fast-acting Human Insulin market.

Key Features:

The report on Fast-acting Human Insulin market reflects various aspects and provide valuable insights into the industry.

Market Size and Growth: The research report provide an overview of the current size and growth of the Fast-acting Human Insulin market. It may include historical data, market segmentation by Type (e.g., Lispro Insulin, Aspart Insulin), and regional breakdowns.

Market Drivers and Challenges: The report can identify and analyse the factors driving



the growth of the Fast-acting Human Insulin market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.

Competitive Landscape: The research report provides analysis of the competitive landscape within the Fast-acting Human Insulin market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.

Technological Developments: The research report can delve into the latest technological developments in the Fast-acting Human Insulin industry. This include advancements in Fast-acting Human Insulin technology, Fast-acting Human Insulin new entrants, Fast-acting Human Insulin new investment, and other innovations that are shaping the future of Fast-acting Human Insulin.

Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Fast-acting Human Insulin market. It includes factors influencing customer ' purchasing decisions, preferences for Fast-acting Human Insulin product.

Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Fast-acting Human Insulin market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Fast-acting Human Insulin market. The report also evaluates the effectiveness of these policies in driving market growth.

Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Fast-acting Human Insulin market.

Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Fast-acting Human Insulin industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.

Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Fast-acting Human Insulin market.



Market Segmentation:

Fast-acting Human Insulin market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.

Segmentation by type

Lispro Insulin

Aspart Insulin

Glulisine Insulin

Segmentation by application

Type 1 Diabetes

Type 2 Diabetes

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China



Japan

Korea

Southeast Asia

India

Australia

#### Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.



Sanofi

Geropharm

Wockhardt

Novo Nordisk

Eli Lilly and Company

Mannkind

Biocon

Julphar

ADOCIA

Tonghua Dongbao Pharmaceutical

Gan & Lee Pharmaceuticals

Zhejiang Hisun Pharmaceutical

Wuhan Biology Chemical Pharmacy

Key Questions Addressed in this Report

What is the 10-year outlook for the global Fast-acting Human Insulin market?

What factors are driving Fast-acting Human Insulin market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Fast-acting Human Insulin market opportunities vary by end market size?

How does Fast-acting Human Insulin break out type, application?



## Contents

#### **1 SCOPE OF THE REPORT**

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

#### **2 EXECUTIVE SUMMARY**

- 2.1 World Market Overview
  - 2.1.1 Global Fast-acting Human Insulin Annual Sales 2018-2029
- 2.1.2 World Current & Future Analysis for Fast-acting Human Insulin by Geographic Region, 2018, 2022 & 2029
- 2.1.3 World Current & Future Analysis for Fast-acting Human Insulin by
- Country/Region, 2018, 2022 & 2029
- 2.2 Fast-acting Human Insulin Segment by Type
  - 2.2.1 Lispro Insulin
  - 2.2.2 Aspart Insulin
  - 2.2.3 Glulisine Insulin
- 2.3 Fast-acting Human Insulin Sales by Type
  - 2.3.1 Global Fast-acting Human Insulin Sales Market Share by Type (2018-2023)
- 2.3.2 Global Fast-acting Human Insulin Revenue and Market Share by Type

(2018-2023)

2.3.3 Global Fast-acting Human Insulin Sale Price by Type (2018-2023)

2.4 Fast-acting Human Insulin Segment by Application

- 2.4.1 Type 1 Diabetes
- 2.4.2 Type 2 Diabetes
- 2.5 Fast-acting Human Insulin Sales by Application
- 2.5.1 Global Fast-acting Human Insulin Sale Market Share by Application (2018-2023)
- 2.5.2 Global Fast-acting Human Insulin Revenue and Market Share by Application (2018-2023)
- 2.5.3 Global Fast-acting Human Insulin Sale Price by Application (2018-2023)



#### **3 GLOBAL FAST-ACTING HUMAN INSULIN BY COMPANY**

- 3.1 Global Fast-acting Human Insulin Breakdown Data by Company 3.1.1 Global Fast-acting Human Insulin Annual Sales by Company (2018-2023) 3.1.2 Global Fast-acting Human Insulin Sales Market Share by Company (2018-2023) 3.2 Global Fast-acting Human Insulin Annual Revenue by Company (2018-2023) 3.2.1 Global Fast-acting Human Insulin Revenue by Company (2018-2023) 3.2.2 Global Fast-acting Human Insulin Revenue Market Share by Company (2018 - 2023)3.3 Global Fast-acting Human Insulin Sale Price by Company 3.4 Key Manufacturers Fast-acting Human Insulin Producing Area Distribution, Sales Area, Product Type 3.4.1 Key Manufacturers Fast-acting Human Insulin Product Location Distribution 3.4.2 Players Fast-acting Human Insulin Products Offered 3.5 Market Concentration Rate Analysis 3.5.1 Competition Landscape Analysis 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023) 3.6 New Products and Potential Entrants
- 3.7 Mergers & Acquisitions, Expansion

#### 4 WORLD HISTORIC REVIEW FOR FAST-ACTING HUMAN INSULIN BY GEOGRAPHIC REGION

4.1 World Historic Fast-acting Human Insulin Market Size by Geographic Region (2018-2023)

4.1.1 Global Fast-acting Human Insulin Annual Sales by Geographic Region (2018-2023)

4.1.2 Global Fast-acting Human Insulin Annual Revenue by Geographic Region (2018-2023)

4.2 World Historic Fast-acting Human Insulin Market Size by Country/Region (2018-2023)

4.2.1 Global Fast-acting Human Insulin Annual Sales by Country/Region (2018-2023)

4.2.2 Global Fast-acting Human Insulin Annual Revenue by Country/Region (2018-2023)

- 4.3 Americas Fast-acting Human Insulin Sales Growth
- 4.4 APAC Fast-acting Human Insulin Sales Growth
- 4.5 Europe Fast-acting Human Insulin Sales Growth
- 4.6 Middle East & Africa Fast-acting Human Insulin Sales Growth



#### **5 AMERICAS**

- 5.1 Americas Fast-acting Human Insulin Sales by Country
- 5.1.1 Americas Fast-acting Human Insulin Sales by Country (2018-2023)
- 5.1.2 Americas Fast-acting Human Insulin Revenue by Country (2018-2023)
- 5.2 Americas Fast-acting Human Insulin Sales by Type
- 5.3 Americas Fast-acting Human Insulin Sales by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

#### 6 APAC

- 6.1 APAC Fast-acting Human Insulin Sales by Region
  - 6.1.1 APAC Fast-acting Human Insulin Sales by Region (2018-2023)
  - 6.1.2 APAC Fast-acting Human Insulin Revenue by Region (2018-2023)
- 6.2 APAC Fast-acting Human Insulin Sales by Type
- 6.3 APAC Fast-acting Human Insulin Sales by Application
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan

#### 7 EUROPE

- 7.1 Europe Fast-acting Human Insulin by Country
- 7.1.1 Europe Fast-acting Human Insulin Sales by Country (2018-2023)
- 7.1.2 Europe Fast-acting Human Insulin Revenue by Country (2018-2023)
- 7.2 Europe Fast-acting Human Insulin Sales by Type
- 7.3 Europe Fast-acting Human Insulin Sales by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia



#### 8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Fast-acting Human Insulin by Country
- 8.1.1 Middle East & Africa Fast-acting Human Insulin Sales by Country (2018-2023)
- 8.1.2 Middle East & Africa Fast-acting Human Insulin Revenue by Country (2018-2023)
- 8.2 Middle East & Africa Fast-acting Human Insulin Sales by Type
- 8.3 Middle East & Africa Fast-acting Human Insulin Sales by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

#### 9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

#### **10 MANUFACTURING COST STRUCTURE ANALYSIS**

- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Fast-acting Human Insulin
- 10.3 Manufacturing Process Analysis of Fast-acting Human Insulin
- 10.4 Industry Chain Structure of Fast-acting Human Insulin

#### 11 MARKETING, DISTRIBUTORS AND CUSTOMER

- 11.1 Sales Channel
- 11.1.1 Direct Channels
- 11.1.2 Indirect Channels
- 11.2 Fast-acting Human Insulin Distributors
- 11.3 Fast-acting Human Insulin Customer

# 12 WORLD FORECAST REVIEW FOR FAST-ACTING HUMAN INSULIN BY GEOGRAPHIC REGION



- 12.1 Global Fast-acting Human Insulin Market Size Forecast by Region
- 12.1.1 Global Fast-acting Human Insulin Forecast by Region (2024-2029)

12.1.2 Global Fast-acting Human Insulin Annual Revenue Forecast by Region (2024-2029)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

- 12.4 Europe Forecast by Country
- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global Fast-acting Human Insulin Forecast by Type
- 12.7 Global Fast-acting Human Insulin Forecast by Application

#### **13 KEY PLAYERS ANALYSIS**

13.1 Sanofi

- 13.1.1 Sanofi Company Information
- 13.1.2 Sanofi Fast-acting Human Insulin Product Portfolios and Specifications
- 13.1.3 Sanofi Fast-acting Human Insulin Sales, Revenue, Price and Gross Margin (2018-2023)
  - 13.1.4 Sanofi Main Business Overview
- 13.1.5 Sanofi Latest Developments
- 13.2 Geropharm
- 13.2.1 Geropharm Company Information
- 13.2.2 Geropharm Fast-acting Human Insulin Product Portfolios and Specifications

13.2.3 Geropharm Fast-acting Human Insulin Sales, Revenue, Price and Gross Margin (2018-2023)

- 13.2.4 Geropharm Main Business Overview
- 13.2.5 Geropharm Latest Developments
- 13.3 Wockhardt
- 13.3.1 Wockhardt Company Information
- 13.3.2 Wockhardt Fast-acting Human Insulin Product Portfolios and Specifications

13.3.3 Wockhardt Fast-acting Human Insulin Sales, Revenue, Price and Gross Margin (2018-2023)

- 13.3.4 Wockhardt Main Business Overview
- 13.3.5 Wockhardt Latest Developments
- 13.4 Novo Nordisk
  - 13.4.1 Novo Nordisk Company Information
  - 13.4.2 Novo Nordisk Fast-acting Human Insulin Product Portfolios and Specifications

13.4.3 Novo Nordisk Fast-acting Human Insulin Sales, Revenue, Price and Gross Margin (2018-2023)



13.4.4 Novo Nordisk Main Business Overview

13.4.5 Novo Nordisk Latest Developments

13.5 Eli Lilly and Company

13.5.1 Eli Lilly and Company Company Information

13.5.2 Eli Lilly and Company Fast-acting Human Insulin Product Portfolios and Specifications

13.5.3 Eli Lilly and Company Fast-acting Human Insulin Sales, Revenue, Price and Gross Margin (2018-2023)

13.5.4 Eli Lilly and Company Main Business Overview

13.5.5 Eli Lilly and Company Latest Developments

13.6 Mannkind

13.6.1 Mannkind Company Information

13.6.2 Mannkind Fast-acting Human Insulin Product Portfolios and Specifications

13.6.3 Mannkind Fast-acting Human Insulin Sales, Revenue, Price and Gross Margin (2018-2023)

13.6.4 Mannkind Main Business Overview

13.6.5 Mannkind Latest Developments

13.7 Biocon

- 13.7.1 Biocon Company Information
- 13.7.2 Biocon Fast-acting Human Insulin Product Portfolios and Specifications
- 13.7.3 Biocon Fast-acting Human Insulin Sales, Revenue, Price and Gross Margin (2018-2023)

13.7.4 Biocon Main Business Overview

13.7.5 Biocon Latest Developments

13.8 Julphar

- 13.8.1 Julphar Company Information
- 13.8.2 Julphar Fast-acting Human Insulin Product Portfolios and Specifications

13.8.3 Julphar Fast-acting Human Insulin Sales, Revenue, Price and Gross Margin (2018-2023)

13.8.4 Julphar Main Business Overview

13.8.5 Julphar Latest Developments

13.9 ADOCIA

- 13.9.1 ADOCIA Company Information
- 13.9.2 ADOCIA Fast-acting Human Insulin Product Portfolios and Specifications

13.9.3 ADOCIA Fast-acting Human Insulin Sales, Revenue, Price and Gross Margin (2018-2023)

- 13.9.4 ADOCIA Main Business Overview
- 13.9.5 ADOCIA Latest Developments
- 13.10 Tonghua Dongbao Pharmaceutical



13.10.1 Tonghua Dongbao Pharmaceutical Company Information

13.10.2 Tonghua Dongbao Pharmaceutical Fast-acting Human Insulin Product Portfolios and Specifications

13.10.3 Tonghua Dongbao Pharmaceutical Fast-acting Human Insulin Sales, Revenue, Price and Gross Margin (2018-2023)

13.10.4 Tonghua Dongbao Pharmaceutical Main Business Overview

13.10.5 Tonghua Dongbao Pharmaceutical Latest Developments

13.11 Gan & Lee Pharmaceuticals

13.11.1 Gan & Lee Pharmaceuticals Company Information

13.11.2 Gan & Lee Pharmaceuticals Fast-acting Human Insulin Product Portfolios and Specifications

13.11.3 Gan & Lee Pharmaceuticals Fast-acting Human Insulin Sales, Revenue, Price and Gross Margin (2018-2023)

13.11.4 Gan & Lee Pharmaceuticals Main Business Overview

13.11.5 Gan & Lee Pharmaceuticals Latest Developments

13.12 Zhejiang Hisun Pharmaceutical

13.12.1 Zhejiang Hisun Pharmaceutical Company Information

13.12.2 Zhejiang Hisun Pharmaceutical Fast-acting Human Insulin Product Portfolios and Specifications

13.12.3 Zhejiang Hisun Pharmaceutical Fast-acting Human Insulin Sales, Revenue, Price and Gross Margin (2018-2023)

13.12.4 Zhejiang Hisun Pharmaceutical Main Business Overview

13.12.5 Zhejiang Hisun Pharmaceutical Latest Developments

13.13 Wuhan Biology Chemical Pharmacy

13.13.1 Wuhan Biology Chemical Pharmacy Company Information

13.13.2 Wuhan Biology Chemical Pharmacy Fast-acting Human Insulin Product Portfolios and Specifications

13.13.3 Wuhan Biology Chemical Pharmacy Fast-acting Human Insulin Sales, Revenue, Price and Gross Margin (2018-2023)

13.13.4 Wuhan Biology Chemical Pharmacy Main Business Overview

13.13.5 Wuhan Biology Chemical Pharmacy Latest Developments

#### 14 RESEARCH FINDINGS AND CONCLUSION



# **List Of Tables**

#### LIST OF TABLES

Table 1. Fast-acting Human Insulin Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & (\$ millions) Table 2. Fast-acting Human Insulin Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & (\$ millions) Table 3. Major Players of Lispro Insulin Table 4. Major Players of Aspart Insulin Table 5. Major Players of Glulisine Insulin Table 6. Global Fast-acting Human Insulin Sales by Type (2018-2023) & (K Units) Table 7. Global Fast-acting Human Insulin Sales Market Share by Type (2018-2023) Table 8. Global Fast-acting Human Insulin Revenue by Type (2018-2023) & (\$ million) Table 9. Global Fast-acting Human Insulin Revenue Market Share by Type (2018-2023) Table 10. Global Fast-acting Human Insulin Sale Price by Type (2018-2023) & (US\$/Unit) Table 11. Global Fast-acting Human Insulin Sales by Application (2018-2023) & (K Units) Table 12. Global Fast-acting Human Insulin Sales Market Share by Application (2018 - 2023)Table 13. Global Fast-acting Human Insulin Revenue by Application (2018-2023) Table 14. Global Fast-acting Human Insulin Revenue Market Share by Application (2018-2023)Table 15. Global Fast-acting Human Insulin Sale Price by Application (2018-2023) & (US\$/Unit) Table 16. Global Fast-acting Human Insulin Sales by Company (2018-2023) & (K Units) Table 17. Global Fast-acting Human Insulin Sales Market Share by Company (2018-2023)Table 18. Global Fast-acting Human Insulin Revenue by Company (2018-2023) (\$ Millions) Table 19. Global Fast-acting Human Insulin Revenue Market Share by Company (2018 - 2023)Table 20. Global Fast-acting Human Insulin Sale Price by Company (2018-2023) & (US\$/Unit) Table 21. Key Manufacturers Fast-acting Human Insulin Producing Area Distribution and Sales Area Table 22. Players Fast-acting Human Insulin Products Offered Table 23. Fast-acting Human Insulin Concentration Ratio (CR3, CR5 and CR10) &



(2018-2023)

Table 24. New Products and Potential Entrants

Table 25. Mergers & Acquisitions, Expansion

Table 26. Global Fast-acting Human Insulin Sales by Geographic Region (2018-2023) & (K Units)

Table 27. Global Fast-acting Human Insulin Sales Market Share Geographic Region (2018-2023)

Table 28. Global Fast-acting Human Insulin Revenue by Geographic Region (2018-2023) & (\$ millions)

Table 29. Global Fast-acting Human Insulin Revenue Market Share by Geographic Region (2018-2023)

Table 30. Global Fast-acting Human Insulin Sales by Country/Region (2018-2023) & (K Units)

Table 31. Global Fast-acting Human Insulin Sales Market Share by Country/Region (2018-2023)

Table 32. Global Fast-acting Human Insulin Revenue by Country/Region (2018-2023) & (\$ millions)

Table 33. Global Fast-acting Human Insulin Revenue Market Share by Country/Region (2018-2023)

Table 34. Americas Fast-acting Human Insulin Sales by Country (2018-2023) & (K Units)

Table 35. Americas Fast-acting Human Insulin Sales Market Share by Country (2018-2023)

Table 36. Americas Fast-acting Human Insulin Revenue by Country (2018-2023) & (\$ Millions)

Table 37. Americas Fast-acting Human Insulin Revenue Market Share by Country (2018-2023)

Table 38. Americas Fast-acting Human Insulin Sales by Type (2018-2023) & (K Units) Table 39. Americas Fast-acting Human Insulin Sales by Application (2018-2023) & (K Units)

Table 40. APAC Fast-acting Human Insulin Sales by Region (2018-2023) & (K Units) Table 41. APAC Fast-acting Human Insulin Sales Market Share by Region (2018-2023) Table 42. APAC Fast-acting Human Insulin Revenue by Region (2018-2023) & (\$ Millions)

Table 43. APAC Fast-acting Human Insulin Revenue Market Share by Region(2018-2023)

Table 44. APAC Fast-acting Human Insulin Sales by Type (2018-2023) & (K Units) Table 45. APAC Fast-acting Human Insulin Sales by Application (2018-2023) & (K Units)



Table 46. Europe Fast-acting Human Insulin Sales by Country (2018-2023) & (K Units) Table 47. Europe Fast-acting Human Insulin Sales Market Share by Country (2018-2023)

Table 48. Europe Fast-acting Human Insulin Revenue by Country (2018-2023) & (\$ Millions)

Table 49. Europe Fast-acting Human Insulin Revenue Market Share by Country (2018-2023)

Table 50. Europe Fast-acting Human Insulin Sales by Type (2018-2023) & (K Units) Table 51. Europe Fast-acting Human Insulin Sales by Application (2018-2023) & (K Units)

Table 52. Middle East & Africa Fast-acting Human Insulin Sales by Country (2018-2023) & (K Units)

Table 53. Middle East & Africa Fast-acting Human Insulin Sales Market Share by Country (2018-2023)

Table 54. Middle East & Africa Fast-acting Human Insulin Revenue by Country (2018-2023) & (\$ Millions)

Table 55. Middle East & Africa Fast-acting Human Insulin Revenue Market Share by Country (2018-2023)

Table 56. Middle East & Africa Fast-acting Human Insulin Sales by Type (2018-2023) & (K Units)

Table 57. Middle East & Africa Fast-acting Human Insulin Sales by Application (2018-2023) & (K Units)

Table 58. Key Market Drivers & Growth Opportunities of Fast-acting Human Insulin

Table 59. Key Market Challenges & Risks of Fast-acting Human Insulin

Table 60. Key Industry Trends of Fast-acting Human Insulin

Table 61. Fast-acting Human Insulin Raw Material

Table 62. Key Suppliers of Raw Materials

Table 63. Fast-acting Human Insulin Distributors List

Table 64. Fast-acting Human Insulin Customer List

Table 65. Global Fast-acting Human Insulin Sales Forecast by Region (2024-2029) & (K Units)

Table 66. Global Fast-acting Human Insulin Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 67. Americas Fast-acting Human Insulin Sales Forecast by Country (2024-2029) & (K Units)

Table 68. Americas Fast-acting Human Insulin Revenue Forecast by Country(2024-2029) & (\$ millions)

Table 69. APAC Fast-acting Human Insulin Sales Forecast by Region (2024-2029) & (K Units)



Table 70. APAC Fast-acting Human Insulin Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 71. Europe Fast-acting Human Insulin Sales Forecast by Country (2024-2029) & (K Units)

Table 72. Europe Fast-acting Human Insulin Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 73. Middle East & Africa Fast-acting Human Insulin Sales Forecast by Country (2024-2029) & (K Units)

Table 74. Middle East & Africa Fast-acting Human Insulin Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 75. Global Fast-acting Human Insulin Sales Forecast by Type (2024-2029) & (K Units)

Table 76. Global Fast-acting Human Insulin Revenue Forecast by Type (2024-2029) & (\$ Millions)

Table 77. Global Fast-acting Human Insulin Sales Forecast by Application (2024-2029) & (K Units)

Table 78. Global Fast-acting Human Insulin Revenue Forecast by Application (2024-2029) & (\$ Millions)

Table 79. Sanofi Basic Information, Fast-acting Human Insulin Manufacturing Base, Sales Area and Its Competitors

Table 80. Sanofi Fast-acting Human Insulin Product Portfolios and Specifications

Table 81. Sanofi Fast-acting Human Insulin Sales (K Units), Revenue (\$ Million), Price

(US\$/Unit) and Gross Margin (2018-2023)

Table 82. Sanofi Main Business

Table 83. Sanofi Latest Developments

Table 84. Geropharm Basic Information, Fast-acting Human Insulin Manufacturing

Base, Sales Area and Its Competitors

 Table 85. Geropharm Fast-acting Human Insulin Product Portfolios and Specifications

Table 86. Geropharm Fast-acting Human Insulin Sales (K Units), Revenue (\$ Million),

Price (US\$/Unit) and Gross Margin (2018-2023)

Table 87. Geropharm Main Business

 Table 88. Geropharm Latest Developments

Table 89. Wockhardt Basic Information, Fast-acting Human Insulin Manufacturing Base, Sales Area and Its Competitors

Table 90. Wockhardt Fast-acting Human Insulin Product Portfolios and Specifications

Table 91. Wockhardt Fast-acting Human Insulin Sales (K Units), Revenue (\$ Million),

Price (US\$/Unit) and Gross Margin (2018-2023)

Table 92. Wockhardt Main Business

Table 93. Wockhardt Latest Developments



Table 94. Novo Nordisk Basic Information, Fast-acting Human Insulin Manufacturing Base, Sales Area and Its Competitors

Table 95. Novo Nordisk Fast-acting Human Insulin Product Portfolios and Specifications

Table 96. Novo Nordisk Fast-acting Human Insulin Sales (K Units), Revenue (\$ Million),

Price (US\$/Unit) and Gross Margin (2018-2023)

Table 97. Novo Nordisk Main Business

Table 98. Novo Nordisk Latest Developments

Table 99. Eli Lilly and Company Basic Information, Fast-acting Human Insulin

Manufacturing Base, Sales Area and Its Competitors

Table 100. Eli Lilly and Company Fast-acting Human Insulin Product Portfolios and Specifications

Table 101. Eli Lilly and Company Fast-acting Human Insulin Sales (K Units), Revenue

(\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 102. Eli Lilly and Company Main Business

Table 103. Eli Lilly and Company Latest Developments

Table 104. Mannkind Basic Information, Fast-acting Human Insulin Manufacturing Base, Sales Area and Its Competitors

Table 105. Mannkind Fast-acting Human Insulin Product Portfolios and Specifications

Table 106. Mannkind Fast-acting Human Insulin Sales (K Units), Revenue (\$ Million),

Price (US\$/Unit) and Gross Margin (2018-2023)

Table 107. Mannkind Main Business

Table 108. Mannkind Latest Developments

Table 109. Biocon Basic Information, Fast-acting Human Insulin Manufacturing Base,

Sales Area and Its Competitors

Table 110. Biocon Fast-acting Human Insulin Product Portfolios and Specifications

Table 111. Biocon Fast-acting Human Insulin Sales (K Units), Revenue (\$ Million), Price

(US\$/Unit) and Gross Margin (2018-2023)

Table 112. Biocon Main Business

Table 113. Biocon Latest Developments

Table 114. Julphar Basic Information, Fast-acting Human Insulin Manufacturing Base,

Sales Area and Its Competitors

Table 115. Julphar Fast-acting Human Insulin Product Portfolios and Specifications

Table 116. Julphar Fast-acting Human Insulin Sales (K Units), Revenue (\$ Million),

Price (US\$/Unit) and Gross Margin (2018-2023)

Table 117. Julphar Main Business

Table 118. Julphar Latest Developments

Table 119. ADOCIA Basic Information, Fast-acting Human Insulin Manufacturing Base, Sales Area and Its Competitors

Table 120. ADOCIA Fast-acting Human Insulin Product Portfolios and Specifications



Table 121. ADOCIA Fast-acting Human Insulin Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 122. ADOCIA Main Business

Table 123. ADOCIA Latest Developments

Table 124. Tonghua Dongbao Pharmaceutical Basic Information, Fast-acting Human Insulin Manufacturing Base, Sales Area and Its Competitors

Table 125. Tonghua Dongbao Pharmaceutical Fast-acting Human Insulin ProductPortfolios and Specifications

Table 126. Tonghua Dongbao Pharmaceutical Fast-acting Human Insulin Sales (K

Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 127. Tonghua Dongbao Pharmaceutical Main Business

Table 128. Tonghua Dongbao Pharmaceutical Latest Developments

Table 129. Gan & Lee Pharmaceuticals Basic Information, Fast-acting Human Insulin Manufacturing Base, Sales Area and Its Competitors

Table 130. Gan & Lee Pharmaceuticals Fast-acting Human Insulin Product Portfolios and Specifications

Table 131. Gan & Lee Pharmaceuticals Fast-acting Human Insulin Sales (K Units),

Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 132. Gan & Lee Pharmaceuticals Main Business

Table 133. Gan & Lee Pharmaceuticals Latest Developments

Table 134. Zhejiang Hisun Pharmaceutical Basic Information, Fast-acting Human

Insulin Manufacturing Base, Sales Area and Its Competitors

Table 135. Zhejiang Hisun Pharmaceutical Fast-acting Human Insulin Product Portfolios and Specifications

Table 136. Zhejiang Hisun Pharmaceutical Fast-acting Human Insulin Sales (K Units),

Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 137. Zhejiang Hisun Pharmaceutical Main Business

Table 138. Zhejiang Hisun Pharmaceutical Latest Developments

Table 139. Wuhan Biology Chemical Pharmacy Basic Information, Fast-acting Human Insulin Manufacturing Base, Sales Area and Its Competitors

Table 140. Wuhan Biology Chemical Pharmacy Fast-acting Human Insulin Product Portfolios and Specifications

Table 141. Wuhan Biology Chemical Pharmacy Fast-acting Human Insulin Sales (K

Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 142. Wuhan Biology Chemical Pharmacy Main Business

Table 143. Wuhan Biology Chemical Pharmacy Latest Developments



# **List Of Figures**

#### LIST OF FIGURES

- Figure 1. Picture of Fast-acting Human Insulin
- Figure 2. Fast-acting Human Insulin Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Fast-acting Human Insulin Sales Growth Rate 2018-2029 (K Units)
- Figure 7. Global Fast-acting Human Insulin Revenue Growth Rate 2018-2029 (\$ Millions)

Figure 8. Fast-acting Human Insulin Sales by Region (2018, 2022 & 2029) & (\$ Millions) Figure 9. Product Picture of Lispro Insulin

- Figure 10. Product Picture of Aspart Insulin
- Figure 11. Product Picture of Glulisine Insulin
- Figure 12. Global Fast-acting Human Insulin Sales Market Share by Type in 2022
- Figure 13. Global Fast-acting Human Insulin Revenue Market Share by Type (2018-2023)
- Figure 14. Fast-acting Human Insulin Consumed in Type 1 Diabetes
- Figure 15. Global Fast-acting Human Insulin Market: Type 1 Diabetes (2018-2023) & (K Units)
- Figure 16. Fast-acting Human Insulin Consumed in Type 2 Diabetes
- Figure 17. Global Fast-acting Human Insulin Market: Type 2 Diabetes (2018-2023) & (K Units)
- Figure 18. Global Fast-acting Human Insulin Sales Market Share by Application (2022)
- Figure 19. Global Fast-acting Human Insulin Revenue Market Share by Application in 2022
- Figure 20. Fast-acting Human Insulin Sales Market by Company in 2022 (K Units)
- Figure 21. Global Fast-acting Human Insulin Sales Market Share by Company in 2022
- Figure 22. Fast-acting Human Insulin Revenue Market by Company in 2022 (\$ Million)
- Figure 23. Global Fast-acting Human Insulin Revenue Market Share by Company in 2022
- Figure 24. Global Fast-acting Human Insulin Sales Market Share by Geographic Region (2018-2023)

Figure 25. Global Fast-acting Human Insulin Revenue Market Share by Geographic Region in 2022

- Figure 26. Americas Fast-acting Human Insulin Sales 2018-2023 (K Units)
- Figure 27. Americas Fast-acting Human Insulin Revenue 2018-2023 (\$ Millions)



Figure 28. APAC Fast-acting Human Insulin Sales 2018-2023 (K Units) Figure 29. APAC Fast-acting Human Insulin Revenue 2018-2023 (\$ Millions) Figure 30. Europe Fast-acting Human Insulin Sales 2018-2023 (K Units) Figure 31. Europe Fast-acting Human Insulin Revenue 2018-2023 (\$ Millions) Figure 32. Middle East & Africa Fast-acting Human Insulin Sales 2018-2023 (K Units) Figure 33. Middle East & Africa Fast-acting Human Insulin Revenue 2018-2023 (\$ Millions) Figure 34. Americas Fast-acting Human Insulin Sales Market Share by Country in 2022 Figure 35. Americas Fast-acting Human Insulin Revenue Market Share by Country in 2022 Figure 36. Americas Fast-acting Human Insulin Sales Market Share by Type (2018-2023)Figure 37. Americas Fast-acting Human Insulin Sales Market Share by Application (2018 - 2023)Figure 38. United States Fast-acting Human Insulin Revenue Growth 2018-2023 (\$ Millions) Figure 39. Canada Fast-acting Human Insulin Revenue Growth 2018-2023 (\$ Millions) Figure 40. Mexico Fast-acting Human Insulin Revenue Growth 2018-2023 (\$ Millions) Figure 41. Brazil Fast-acting Human Insulin Revenue Growth 2018-2023 (\$ Millions) Figure 42. APAC Fast-acting Human Insulin Sales Market Share by Region in 2022 Figure 43. APAC Fast-acting Human Insulin Revenue Market Share by Regions in 2022 Figure 44. APAC Fast-acting Human Insulin Sales Market Share by Type (2018-2023) Figure 45. APAC Fast-acting Human Insulin Sales Market Share by Application (2018 - 2023)Figure 46. China Fast-acting Human Insulin Revenue Growth 2018-2023 (\$ Millions) Figure 47. Japan Fast-acting Human Insulin Revenue Growth 2018-2023 (\$ Millions) Figure 48. South Korea Fast-acting Human Insulin Revenue Growth 2018-2023 (\$ Millions) Figure 49. Southeast Asia Fast-acting Human Insulin Revenue Growth 2018-2023 (\$ Millions) Figure 50. India Fast-acting Human Insulin Revenue Growth 2018-2023 (\$ Millions) Figure 51. Australia Fast-acting Human Insulin Revenue Growth 2018-2023 (\$ Millions) Figure 52. China Taiwan Fast-acting Human Insulin Revenue Growth 2018-2023 (\$ Millions) Figure 53. Europe Fast-acting Human Insulin Sales Market Share by Country in 2022 Figure 54. Europe Fast-acting Human Insulin Revenue Market Share by Country in 2022 Figure 55. Europe Fast-acting Human Insulin Sales Market Share by Type (2018-2023)

Figure 56. Europe Fast-acting Human Insulin Sales Market Share by Application



(2018-2023)

Figure 57. Germany Fast-acting Human Insulin Revenue Growth 2018-2023 (\$ Millions)

Figure 58. France Fast-acting Human Insulin Revenue Growth 2018-2023 (\$ Millions)

Figure 59. UK Fast-acting Human Insulin Revenue Growth 2018-2023 (\$ Millions)

Figure 60. Italy Fast-acting Human Insulin Revenue Growth 2018-2023 (\$ Millions)

Figure 61. Russia Fast-acting Human Insulin Revenue Growth 2018-2023 (\$ Millions)

Figure 62. Middle East & Africa Fast-acting Human Insulin Sales Market Share by Country in 2022

Figure 63. Middle East & Africa Fast-acting Human Insulin Revenue Market Share by Country in 2022

Figure 64. Middle East & Africa Fast-acting Human Insulin Sales Market Share by Type (2018-2023)

Figure 65. Middle East & Africa Fast-acting Human Insulin Sales Market Share by Application (2018-2023)

Figure 66. Egypt Fast-acting Human Insulin Revenue Growth 2018-2023 (\$ Millions)

Figure 67. South Africa Fast-acting Human Insulin Revenue Growth 2018-2023 (\$ Millions)

Figure 68. Israel Fast-acting Human Insulin Revenue Growth 2018-2023 (\$ Millions)

Figure 69. Turkey Fast-acting Human Insulin Revenue Growth 2018-2023 (\$ Millions)

Figure 70. GCC Country Fast-acting Human Insulin Revenue Growth 2018-2023 (\$ Millions)

Figure 71. Manufacturing Cost Structure Analysis of Fast-acting Human Insulin in 2022

Figure 72. Manufacturing Process Analysis of Fast-acting Human Insulin

Figure 73. Industry Chain Structure of Fast-acting Human Insulin

Figure 74. Channels of Distribution

Figure 75. Global Fast-acting Human Insulin Sales Market Forecast by Region (2024-2029)

Figure 76. Global Fast-acting Human Insulin Revenue Market Share Forecast by Region (2024-2029)

Figure 77. Global Fast-acting Human Insulin Sales Market Share Forecast by Type (2024-2029)

Figure 78. Global Fast-acting Human Insulin Revenue Market Share Forecast by Type (2024-2029)

Figure 79. Global Fast-acting Human Insulin Sales Market Share Forecast by Application (2024-2029)

Figure 80. Global Fast-acting Human Insulin Revenue Market Share Forecast by Application (2024-2029)



#### I would like to order

Product name: Global Fast-acting Human Insulin Market Growth 2023-2029 Product link: <u>https://marketpublishers.com/r/G3DA527E3398EN.html</u>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

#### Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/G3DA527E3398EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

\*\*All fields are required

Custumer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970